ROBIN DANIEL: Open Payments
NPI 1437490059 · PARAMUS, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,648 in 92 payments from 10 companies in 2025. Trend: 2023 $939 · 2024 $1,329 · 2025 $1,648
Food & beverage: $1,537Education: $111
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 20 | $388 |
| Teva Pharmaceuticals USA, Inc. | 20 | $377 |
| Otsuka America Pharmaceutical, Inc. | 19 | $319 |
| Lundbeck LLC | 10 | $177 |
| E.R. Squibb & Sons, L.L.C. | 9 | $155 |
| Janssen Pharmaceuticals, Inc | 6 | $98 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $51 |
| Axsome Therapeutics, Inc. | 3 | $51 |
| Neurocrine BioSciences, Inc. | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
Products named: ARISTADA, ABILIFY ASIMTUFII, ABILIFY MAINTENA, UZEDY, COBENFY, AUSTEDO XR, INVEGA SUSTENNA, CAPLYTA.
Industry payments across NJ — which companies pay providers there.
